International journal of clinical pharmacology and therapeutics最新文献

{"title":"Recovery from liraglutide-induced acute liver injury assessed for causality using the updated RUCAM as global gold standard: A case report and literature review.","authors":"Fenli Su, WeiChi Lu","doi":"10.5414/CP205028","DOIUrl":"https://doi.org/10.5414/CP205028","url":null,"abstract":"<p><p>Liraglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) widely used for managing type 2 diabetes mellitus (T2DM) and obesity. Reports of liraglutide-associated hepatotoxicity are exceedingly rare. To our knowledge, this is the 9^th case of drug-induced liver injury (DILI) caused by liraglutide to be reported. We present a case of a 40-year-old Chinese woman who developed acute liver injury with elevated liver enzymes following 2 weeks of liraglutide treatment for T2DM. Causality was assessed using the updated RUCAM scale, yielding a score of 7, indicating probable DILI, and the diagnosis was further confirmed by liver biopsy. Liver enzyme levels normalized after discontinuing the drug and administering liver-protective treatment within 3 weeks. Furthermore, this case report includes a comprehensive review of all published cases of liraglutide-associated DILI, emphasizing the necessity of regular hepatic-biochemistry monitoring in patients receiving GLP-1 receptor agonists such as liraglutide and providing meaningful evidence regarding their hepatotoxic risk.</p>","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tyrosine kinase inhibitor (second-generation)-related pancreatic toxicity in chronic myeloid leukemia patients analyzed using the FAERS database.","authors":"Shiyu Wang, Qingmao Luo, Ning He, Yu Zou, Jinglun Lai, Wenyan Yi, Jiahao Chen","doi":"10.5414/CP204979","DOIUrl":"https://doi.org/10.5414/CP204979","url":null,"abstract":"<p><strong>Objective: </strong>To analyze pharmacovigilance data for second-generation tyrosine kinase inhibitor (TKI)-related acute pancreatic toxicity in chronic myeloid leukemia (CML) patients contained in the FAERS database.</p><p><strong>Materials and methods: </strong>This observational pharmacovigilance study examined reports for the period Q1 2016 to Q3 2025. Disproportionality analysis was performed using four procedures: i) reporting odds ratio (ROR), ii) proportional reporting ratio (PRR), iii) Bayesian confidence propagation neural network (BCPNN), and iv) multi-item gamma Poisson shrinker (MGPS).</p><p><strong>Results: </strong>Of the 16,057,190 adverse events (AEs) retrieved, 24,803, 31,487, and 11,404 were linked to nilotinib, dasatinib, and bosutinib, respectively. Nilotinib exhibited the strongest and broadest risk signals, including significant associations with pancreatitis (ROR = 10.84), acute pancreatitis, elevated amylase (ROR = 19.94) and lipase (ROR = 14.25), and increased bilirubin (ROR = 11.40), indicating clear pancreatic toxicity with potential hepatic involvement and abdominal symptoms. Bosutinib primarily signaled intense and upper abdominal pain (ROR = 5.04 - 5.44), with weaker signals for pancreatitis. Dasatinib showed the weakest signals, mainly elevated amylase (ROR = 4.79) and lipase (ROR = 8.57). Four algorithms yielded 12 positive signals (17.39% of total). Median age was 52 - 58 years; onset of AEs typically occurred within 30 days of commencing treatment.</p><p><strong>Conclusion: </strong>Pharmacovigilance data in the FAERS database showed strongest pancreatic/gastrointestinal toxicity signals for nilotinib, indicating the need for close monitoring, followed next by bosutinib, with dasatinib exhibiting the weakest signals of the 3 agents. These findings arising from patient therapy serve as a valuable guide for decisions on drug selection, risk management, and future research.</p>","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elucidating the multi-target therapeutic mechanism of Kangtai decoction in lung cancer through integrated network pharmacology and molecular docking.","authors":"Jing Niu, Yang Yang, Yang Hui, Chaoli Feng","doi":"10.5414/CP205003","DOIUrl":"https://doi.org/10.5414/CP205003","url":null,"abstract":"<p><strong>Background: </strong>Lung cancer is the leading cause of cancer-related death worldwide, with a high incidence and limited effective treatments, the main focus being on symptom management and tumor control. Kangtai decoction (KTD), a traditional Chinese medicine, has shown promising results in alleviating lung cancer symptoms and improving quality of life in China, though its precise mechanism of action remains unclear.</p><p><strong>Objective: </strong>This study employed a network pharmacology-based approach, complemented by molecular docking, to identify the bioactive components, key targets, and potential pharmacological mechanisms of KTD against lung cancer.</p><p><strong>Materials and methods: </strong>Bioactive components and drug targets of KTD, along with targets related to lung cancer, were collected from public databases. Bioinformatics analyses, including protein-protein interaction (PPI), gene ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, were conducted to identify core targets, bioactive components, and signaling pathways. Molecular docking was then performed to predict the binding between active compounds and core targets.</p><p><strong>Results: </strong>A total of 145 effective components of KTD for treating lung cancer were screened, along with 113 common targets between KTD and lung cancer. Bioinformatics analysis and molecular docking indicated that in the treatment of lung cancer with KTD, neocryptotanshinone II was the most significant bioactive compound, IL1B was the most pivotal target, and the IL-17 signaling pathway was the most critical pathway.</p><p><strong>Conclusion: </strong>KTD is effective in the treatment of lung cancer, possibly because of the binding of its active components to key therapeutic targets involved in lung cancer.</p>","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149166480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time to onset of amiodarone-induced interstitial lung disease is correlated with the percentage body fat: An analysis of data from the FAERS and JADER databases.","authors":"Takaya Uno, Kouichi Hosomi, Satoshi Yokoyama","doi":"10.5414/CP205006","DOIUrl":"10.5414/CP205006","url":null,"abstract":"<p><strong>Objectives: </strong>To identify the time-to-onset profiles of amiodarone-induced interstitial lung disease using two spontaneous adverse event reporting databases.</p><p><strong>Materials and methods: </strong>Data were obtained from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS; JAPIC AERS) and the Japanese Adverse Drug Event Report database (JADER). Time-to-onset profiles of amiodarone-induced interstitial lung disease were analyzed using the generalized Wilcoxon test. Additionally, because JADER allows estimation of body fat percentage (eBF%), a one-sided Jonckheere-Terpstra test was conducted to evaluate the relationship between eBF% and time-to-onset of amiodarone-induced interstitial lung disease.</p><p><strong>Results: </strong>In FAERS, sex was not significantly associated with the median time-to-onset of interstitial lung disease (male: 187 days; female: 190 days; p = 0.8457). Conversely, in JADER, female patients demonstrated a significantly longer median time-to-onset than male patients (male: 175 days; female: 273 days; p = 0.0214). Furthermore, in the Jonckheere-Terpstra test, patient stratification into healthy weight, overweight, and obesity categories based on eBF% showed a significant increase in median onset time with increasing obesity level in male patients (healthy weight: 96 days; overweight: 185 days; obesity: 272 days; p = 0.0126) but not in female patients (healthy weight: 253 days; overweight: 273 days; obesity: 428.5 days; p = 0.4123).</p><p><strong>Conclusion: </strong>To prevent fatal outcomes, pulmonary function may need to be monitored according to race, sex, and obesity level.</p>","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149109459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-EGFR antibody therapy and skin toxicity: Retrospective analysis and role of pharmacists in protocol-based pharmacotherapy management.","authors":"Hajime Morita, Tomoya Sakurada, Ayami Hirano, Mari Makuuchi, Sayaka Kishimoto, Hiroko Minatogawa, Ikko Sakaue, Yu Sunakawa, Nobunori Sato, Shingo Yamazaki","doi":"10.5414/CP205030","DOIUrl":"10.5414/CP205030","url":null,"abstract":"<p><strong>Objective: </strong>Anti-epidermal growth factor receptor (EGFR) antibodies are a therapy option for patients with advanced or recurrent colorectal cancer. However, these agents frequently cause skin toxicities, which compromise treatment continuity and negatively impact patient quality of life, and evidence regarding pharmacist-led interventions remains limited. We aimed to evaluate pharmacist-led pre-consultation interviews for patients receiving anti-EGFR antibodies by examining pharmacist-physician concordance in skin toxicity assessment, physician acceptance of pharmacist recommendations, and their contribution to dermatological toxicity management and multidisciplinary care.</p><p><strong>Materials and methods: </strong>We conducted a retrospective observational study in 95 patients with colorectal cancer who received anti-EGFR antibody therapy in an outpatient setting between November 2012 and November 2023. Data collected included i) implementation status of pharmacist-led pre-consultation interviews, ii) concordance rates with physicians in skin toxicity grading, iii) acceptance rates of pharmacist-initiated prescriptions, and iv) physician adoption of recommendations regarding dose modifications or dermatology referrals.</p><p><strong>Results: </strong>A total of 1,749 pharmacist-led pre-consultation interviews were conducted, achieving an implementation rate of 96.5%. Concordance rates between pharmacists and physicians for skin toxicity grading were approximately 98 - 99%, and the acceptance rate of pharmacist-initiated prescriptions exceeded 97%. Over 80% of the recommendations for dose adjustments and dermatology consultations were accepted.</p><p><strong>Conclusion: </strong>Pharmacist-led pre-consultation interviews facilitate accurate assessment and timely intervention for skin toxicities and serve as a practical tool to support physicians in treatment decision-making.</p>","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baloxavir marboxil versus oseltamivir phosphate: Efficacy, safety, and economics in patients with influenza.","authors":"Yongli Gu, Daoli Jiang","doi":"10.5414/CP204995","DOIUrl":"10.5414/CP204995","url":null,"abstract":"<p><strong>Aims: </strong>To evaluate the efficacy, safety, and cost-effectiveness of baloxavir marboxil tablets versus oseltamivir phosphate capsules for treatment of influenza from the health-care system perspective.</p><p><strong>Materials and methods: </strong>Influenza patients were assigned to receive baloxavir marboxil (baloxavir group) or oseltamivir phosphate (oseltamivir group) and followed prospectively. Clinical outcomes, adverse events, and direct medical costs during treatment were collected. A cost-effectiveness analysis was performed from the health-care system perspective. Incremental cost-effectiveness ratios (ICERs) were calculated using 48-hour and 5-day recovery rates as effectiveness measures. Sensitivity analyses assessed drivers of results.</p><p><strong>Results: </strong>A total of 102 cases treated with baloxavir and 81 cases treated with oseltamivir were analyzed. There were no significant differences between groups in 5-day overall effectiveness (p = 0.111) or 5-day defervescence rate (p = 0.115). The baloxavir group showed significantly higher 48-hour effectiveness (p < 0.001), 48-hour recovery rate (p < 0.001), 48-hour defervescence rate (p < 0.001), and 5-day recovery rate (p = 0.023) compared with the oseltamivir group. Adverse event incidence was significantly lower in the baloxavir group (p < 0.001). Sensitivity analysis identified the antiviral agent as a significant driver of 48-hour effectiveness (p = 0.004), 48-hour recovery (p = 0.013), and 48-hour defervescence (p = 0.008). Results remained robust across analyses. Total outpatient and drug costs were significantly higher in the baloxavir group (both p < 0.001). Using 48-hour recovery and 5-day recovery as effectiveness endpoints, the ICERs for baloxavir versus oseltamivir were ¥92.23 and ¥794.29 per additional recovered patient, respectively.</p><p><strong>Conclusion: </strong>Baloxavir marboxil is superior to oseltamivir in efficacy, safety, and cost-effectiveness for influenza.</p>","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disproportionate reporting of seizures with histamine H1 receptor antagonists: The role of drug generation and brain H1 receptor occupancy assessed using the Japanese Adverse Drug Event Report database.","authors":"Yu Masabe, Ryo Inose, Kanako Mizuno, Yuichi Muraki","doi":"10.5414/CP205025","DOIUrl":"10.5414/CP205025","url":null,"abstract":"<p><strong>Background: </strong>Histamine H1 receptor antagonists are widely used as antiallergic agents. However, seizure reporting patterns across individual drugs, drug generation, and brain H1 receptor occupancy (H1RO)-based classification have not been comprehensively evaluated.</p><p><strong>Objective: </strong>To evaluate seizure signals for H1 receptor antagonists by drug generation and H1RO-based classification using the Japanese Adverse Drug Event Report (JADER) database.</p><p><strong>Materials and methods: </strong>Reports included in the JADER database from April 2004 to December 2024 were analyzed. Seizure signals for H1 receptor antagonists were evaluated using the reporting odds ratio (ROR). Analyses included all reports and a subgroup of patients under 10 years of age.</p><p><strong>Results: </strong>Overall, seizure signals were detected for selected individual H1 receptor antagonists in both generations, and the observed patterns were not consistently explained by drug generation or H1RO-based classification. As supporting findings, aggregated analyses showed signals for first-generation (ROR: 1.68, 95% CI: 1.46 - 1.93) and second-generation agents (ROR: 1.47, 95% CI: 1.34 - 1.61). In patients under 10 years of age, seizure signals were detected across both drug generations and different H1RO-based categories and were not consistently explained by either classification.</p><p><strong>Conclusion: </strong>These findings suggest that seizure signals differ across individual drugs, with similar patterns observed in children under 10 years of age. Individual drug characteristics and patient age may warrant consideration in drug selection rather than relying solely on drug generation or H1RO-based classification.</p>","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stevens-Johnson syndrome in toddlers: Treatment and prevention using antivirals and vitamin D3.","authors":"Andjelka Stojkovic, Katerina Dajic, Andrijana Kostic, Katarina Cukovic Prokic, Jelena Balovic","doi":"10.5414/CP204999","DOIUrl":"10.5414/CP204999","url":null,"abstract":"","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149016807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Na-dependent glucose transporter-2 inhibitors, bone mineral density, and fracture risk in type-2 diabetes mellitus with osteoporosis: A meta-analysis of 2,000 patients.","authors":"Lingyan Kong, Xuechun Gu","doi":"10.5414/CP204936","DOIUrl":"10.5414/CP204936","url":null,"abstract":"<p><strong>Objective: </strong>We evaluated the effects of sodium-dependent glucose transporter 2 inhibitors (SGLT2i) on bone mineral density (BMD) and fracture risk in patients with type 2 diabetes mellitus (T2DM) and osteoporosis.</p><p><strong>Materials and methods: </strong>Randomized controlled trials (RCTs) published before April 2024 were systematically searched in PubMed, MEDLINE, Web of Science, the Cochrane Library, and EMBASE. Quality assessment was performed by Cochrane Risk of Bias 2 tool. RevMan 5.3 software was employed to conduct meta-analysis. The outcome indicators included glycosylated hemoglobin A1c (HbA1c), BMD change, and fracture incidence rate.</p><p><strong>Results: </strong>A total of 8 studies covering 1,998 subjects were included (1,094 in the SGLT2i group and 904 in the control group). Analysis of 5 studies showed that HbA1c level was significantly lower in the SGLT2i group (mean difference (MD) = -0.11, 95% CI (-0.18 to -0.05) , p = 0.0008). In the 3 studies evaluating bone density, BMD change was significantly higher in the SGLT2i group (standardized MD = 0.69, 95% CI (0.45 - 0.93), p < 0.00001). Based on the 2 studies reporting fracture events, the incidence rate was lower in the SGLT2i group (risk ratio (RR) = 0.09, 95% CI (0.02 - 0.47), p = 0.004).</p><p><strong>Conclusion: </strong>Preliminary evidence suggests that SGLT2i may be associated with modest improvements in BMD and no signal of increased fracture risk in patients with T2DM and osteoporosis. These findings remain to be confirmed in larger and longer-term randomized controlled trials.</p>","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148919099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of hyperglycemia spikes induced by magnesium citrate administration in type 1 diabetes mellitus: A case report and analysis of a large claims database.","authors":"Hiromi Koshizuka, Kenji Momo, Masaki Kida, Ayako Watanabe, Akihisa Tanaka, Yuka Kashiwabara, Mayo Tanabe, Naoyuki Uragami, Haruhiro Inoue, Katsumi Tanaka","doi":"10.5414/CP204937","DOIUrl":"10.5414/CP204937","url":null,"abstract":"<p><strong>Objectives: </strong>To report the occurrence of elevations (spikes) in interstitial fluid glucose concentrations (IFGC) following magnesium citrate administration during preparation for colonoscopy in a patient with type 1 diabetes mellitus (T1DM). To ascertain, using a comprehensive analysis of large claims databases, the proportion of diabetes mellitus (DM) patients who are vulnerable to showing elevated blood glucose levels following magnesium citrate administration.</p><p><strong>Case presentation: </strong>A female patient aged 35 years received pretreatment with 100 g of magnesium citrate in 1.8 L of water 2 hours before a colonoscopy. After an interval of 41 minutes, the patient self-administered insulin to correct an IFGC increase from 108 to 176 mg/dL. However, the IFGC reached a peak of 251 mg/dL, resulting in marked thirst, frequent urination, and palpitations. Based on a database cohort of ~ 3 million patients, there were 105,348 patients with a risk for elevations in the blood glucose level after receiving magnesium citrate, of whom 9.5% (n = 9,957) had DM and 96 had T1DM.</p><p><strong>Conclusion: </strong>Analysis of a colonoscopy patient with T1DM and magnesium citrate-induced elevations in IFGC, and evaluation of patients in a large database with a similar risk, emphasizes the need for caution when administering such agents and in particular in patients with T1DM. We suggest that alternative preparations for colonoscopy in diabetic patients may be warranted.</p>","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148906226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}